Parnassus Investments’s Alnylam Pharmaceuticals ALNY Stock Holding History

Parnassus Investments’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-48,991	Closed	-$16.2M	–	136
2026 Q1	$16.2M	Buy	48,991 +4,431	+10%	+$1.51M	0.05%	106
2025 Q4	$17.7M	Buy	44,560 +7,546	+20%	+$3.34M	0.05%	114
2025 Q3	$16.9M	Sell	37,014 -398	-1%	-$162K	0.04%	119
2025 Q2	$12.2M	Buy	+37,412	New	+$10.4M	0.03%	122
2024 Q2	–	Sell	-38,748	Closed	-$5.79M	–	130
2024 Q1	$5.79M	Hold	38,748	–	–	0.01%	120
2023 Q4	$7.42M	Hold	38,748	–	–	0.02%	114
2023 Q3	$6.86M	Buy	+38,748	New	+$7.39M	0.02%	119
2022 Q4	–	Sell	-25,970	Closed	-$5.2M	–	138
2022 Q3	$5.2M	Sell	25,970 -32,068	-55%	-$6.12M	0.01%	126
2022 Q2	$8.46M	Sell	58,038 -19,549	-25%	-$2.77M	0.02%	124
2022 Q1	$12.7M	Hold	77,587	–	–	0.03%	128
2021 Q4	$13.2M	Hold	77,587	–	–	0.03%	121
2021 Q3	$14.6M	Hold	77,587	–	–	0.03%	119
2021 Q2	$13.2M	Hold	77,587	–	–	0.03%	119
2021 Q1	$11M	Hold	77,587	–	–	0.03%	121
2020 Q4	$10.1M	Buy	+77,587	New	+$10.4M	0.03%	110

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Parnassus Investments's ALNY Position: Q2 2026 in Review

Parnassus Investments sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2026, closing a stake of 48,991 shares — an estimated $16.2M sold.

Parnassus Investments first reported a position in ALNY in Q4 2020 and held it in 15 quarters. The position peaked at $17.7M in Q4 2025. 788 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Parnassus Investments reported no remaining Alnylam Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Parnassus Investments sold 48,991 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $16.2M.
Parnassus Investments first reported a position in Alnylam Pharmaceuticals in Q4 2020 and held it in 15 quarters.
Parnassus Investments's Alnylam Pharmaceuticals position peaked at $17.7M in Q4 2025.
788 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Parnassus Investments's 13F filing for Q2 2026, filed 29 Jul 2026.